d69e622a-6dee-48f3-bf06-7f6148d7472a
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 69
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.360
- MYOGENESIS+0.310
- HEDGEHOG_SIGNALING+0.180
- KRAS_SIGNALING_DN+0.150
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.130
- PROTEIN_SECRETION+0.100
- APICAL_JUNCTION+0.090
- ANDROGEN_RESPONSE+0.040
- SPERMATOGENESIS+0.040
- HEME_METABOLISM+0.030
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.540
- E2F_TARGETS-0.520
- MYC_TARGETS_V2-0.510
- INFLAMMATORY_RESPONSE-0.460
- IL6_JAK_STAT3_SIGNALING-0.440
- G2M_CHECKPOINT-0.420
- GLYCOLYSIS-0.380
- TNFA_SIGNALING_VIA_NFKB-0.350
- INTERFERON_GAMMA_RESPONSE-0.330
- MTORC1_SIGNALING-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CN-4737-01A-01R-1436-07 | — | — | 0.872 |
| 2 | 65f86d9a-828b-4e8b-a656-38baba5a54f7 | — | — | 0.863 |
| 3 | ULC0424T_S49 | — | cohortA1 | 0.863 |
| 4 | ca7ac1e1-4c44-40a5-8094-eeebc0c2c5a2 | — | — | 0.861 |
| 5 | TCGA-B6-A0X7-01A-11R-A10J-07 | — | A | 0.854 |
| 6 | f4cfbfdb-3861-4731-92d8-74e66a7ae5a7 | — | — | 0.852 |
| 7 | 8a25dfb0-edd0-4a44-9a6b-8f3f761b940c | — | — | 0.852 |
| 8 | 4f0b1ac0-c503-4852-9a44-cb4231f4b17b | — | — | 0.849 |
| 9 | 20030014.LumA | — | A | 0.845 |
| 10 | s0122320 | — | — | 0.841 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.360 | Inavolisib | — uncovered |
| MYOGENESIS | 0.310 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.180 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.150 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.130 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.100 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.090 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.040 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.040 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.030 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |